Skip to content
← Full study record

NCT03773107 · MORE INFO

Limitations, agreements, and source contact

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma · Source last updated 2025-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
The Phase II part of the trial did not open to enrollment. The MTD was not identified in the Phase I part of the trial.
point Of Contact
email
james.symanowski@atriumhealth.org
organization
Levine Cancer Institute
phone
9804422371
title
Jim Symanowski, PhD
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
The Phase II part of the trial did not open to enrollment. The MTD was not identified in the Phase I part of the trial.
point Of Contact
email
james.symanowski@atriumhealth.org
organization
Levine Cancer Institute
phone
9804422371
title
Jim Symanowski, PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice